1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Regent Pacific Group Limited

Regent Pacific Group Limited

HHKEX:575
0.81
HKD
-0.01
(-1.23%)
312.24MMarket Cap
Regent Pacific Group Limited
HKEX:575
(Hong Kong Exchange)

Recent

price

0.81

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
0.28
0.23
0.37
0.15
- -
0.01
- -
0.06
0.07
0.01
0.01
0.03
- -
- -
- -
- -
- -
Revenue per Share
3.08
-2.63
-2.82
-1.48
-0.49
-0.54
-0.03
-0.3
-0.34
-0.72
-0.26
-0.11
-0.3
-0.11
-0.02
-0.02
- -
Basic EPS, GAAP
-2.09
-4.1
-0.39
3.04
-0.23
-0.65
-0.11
-0.03
-0.02
-0.1
-0.06
-0.01
- -
-0.02
-0.02
-0.02
- -
Free Cash Flow per Basic Share
0.26
0.54
0.85
3.38
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
13.79
10.44
8.1
3.38
2.8
2.24
2.09
1.73
1.38
0.68
0.42
0.32
0.02
-0.01
-0.03
-0.02
-0.02
Book Value per Share
13.17
10.44
8.1
3.38
2.8
2.05
-0.14
-0.07
-0.11
-0.22
-0.18
-0.08
-0.18
-0.01
-0.03
-0.02
-0.02
Tangible Book Value per Share
19
18
16
17
17
17
74
91
92
92
93
120
120
225
228
261
261
Basic Weighted Avg Shares
5
4
6
3
- -
- -
- -
5
6
1
1
3
- -
- -
1
- -
- -
Sales/Revenue/Turnover
692.27
-163.39
-239.73
-420.82
66,830
-4,069.34
-25,572.26
-605.2
-501.54
-5,919.27
-1,941.14
-872.37
-26,977.19
-9,608.59
-594.44
-1,183.75
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
23
28
28
29
20
24
25
23
- -
- -
- -
Depreciation Expense
60
-49
-45
-26
-9
-9
-2
-27
-31
-66
-24
-13
-36
-25
-4
-5
- -
Net Income, GAAP
1.6
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
1,121.38
-1,125.92
-761.53
-960.15
85,630
-4,402.36
-1,795.62
-522.92
-507.96
-10,517.2
-1,848.11
-387.15
-31,953.51
-8,607.9
-623.37
-1,297.52
- -
Profit Margin (%)
221
149
131
47
16
13
3
8
3
-5
-2
2
-16
-1
-5
-7
-7
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
8
14
8
- -
1
1
- -
- -
LT Debt
272
183
141
59
49
39
181
159
127
63
50
39
3
-2
-6
-7
-7
Total Equity
14.54
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
23.97
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
24.22
-21.48
-27.75
-25.62
-15.91
-21.25
-2.23
-16.08
-21.78
-69.85
-43.25
-28.29
-176.12
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
2
2
4
LT Borrowings
1
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
228
292
292
Market Capitalization
11
38
40

Working Capital

USD

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
1
1
1
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
5
7
Payables & Accruals
- -
- -
- -
ST Debt
2
2
4
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
27.86%
3.41%
12.54%
Free Cash Flow
-85.21%
-211.25%
4.3%
Net Income, GAAP
103.41%
6.51%
5.09%
Sales/Revenue/Turnover
402.39%
60.57%
-49.51%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
1
2025
- -
- -
- -

Semi-annual Earnings Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.11
2024
- -
- -
-0.02
2025
- -
- -
-0.02

Semi-annual Dividends Per Share

USD

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Regent Pacific Group Limited (RPGLF) is an investment holding company that specializes in growth and value-led investments in the healthcare and late-stage life sciences sectors. The company maintains a diversified portfolio encompassing biopharma research, development, and commercialization efforts, including pharmaceutical products for urological disorders such as Fortacin (Senstend in China) for premature ejaculation treatment; artificial intelligence models and tools for aging and longevity research, offered to longevity clinics, preventative medicine organizations, health clubs, insurance companies, and research institutions; and corporate investments in listed and unlisted entities across biopharma, resources, and other sectors. It operates primarily in Europe, the United States, Asia Pacific, and Taiwan, with a focus on out-licensing assets to strategic pharmaceutical partners and returning surplus capital to shareholders. Founded in 1991 and headquartered in Central, Hong Kong, the Cayman Islands-incorporated firm targets pharmaceutical companies, biotech innovators, and institutional investors in healthcare, life sciences, and related industries. Its biopharma segment drives product development and marketing, while the corporate investment segment manages strategic holdings, including legacy natural resources positions. In recent developments, Regent Pacific Group reverted to its original name from Endurance RP Limited in July 2023, reflecting a strategic return to its established branding following the 2021 name change. Strategic partners submitted a New Drug Application (NDA) for Senstend to China's National Medical Products Administration in December 2024, with approval expected by year-end. The company anticipates significantly reduced net losses for 2024, projecting US$4-5 million versus US$25.05 million prior, driven by eliminated amortization and impairment charges on intangible assets. In mid-2024, it terminated a disposal of its West China Coking & Gas stake, issued shares to settle loans, replaced its auditor amid a going-concern note, and reported narrower half-year losses.